DEF: Moleculin Biotech Seeks Stockholder Approval for Warrant Issuance to Comply with Nasdaq Listing Rule

Moleculin Biotech is seeking stockholder approval to issue shares upon the exercise of warrants issued in a private placement to comply with Nasdaq Listing Rule 5635(d).

Summary

• Moleculin Biotech is holding a Special Meeting of Stockholders on April 9, 2025, to vote on two proposals.
• The first proposal, the Nasdaq Proposal, seeks approval for the issuance of up to 6,542,058 shares of common stock upon the exercise of warrants issued in a private placement on February 26, 2025, to comply with Nasdaq Listing Rule 5635(d).
• The second proposal is to approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Proposal.
• The Board of Directors recommends voting FOR both proposals.
• The company engaged Okapi Partners LLC to solicit proxies at an approximate cost of $12,000.
• As of February 28, 2025, there were 13,302,494 shares of common stock outstanding.
• The warrants have an initial exercise price of $1.07 per share and expire five years after shareholder approval.
• If the Nasdaq Proposal is not approved, the warrants will not become exercisable, and the company will not receive potential proceeds of $7.0 million assuming full exercise.
• Approval of the Nasdaq Proposal will result in dilution of existing stockholders' ownership interests.

Sentiment

Score: 7

Explanation: The document is primarily procedural, outlining the need for shareholder approval. The tone is professional and straightforward, with a clear recommendation from the Board. The potential for dilution is a negative, but the potential capital raise is a positive, resulting in a neutral to slightly positive sentiment.

Positives

• Approval of the Nasdaq Proposal would allow the company to potentially receive $7.0 million in proceeds if all warrants are exercised.
• The Board of Directors unanimously recommends voting FOR the proposals.

Negatives

• Approval of the Nasdaq Proposal will result in dilution of existing stockholders' ownership interests.
• If the Nasdaq Proposal is not approved, the company may incur substantial costs to hold additional meetings every 90 days to seek approval.

Risks

• Failure to obtain stockholder approval for the Nasdaq Proposal will prevent the warrants from becoming exercisable, potentially foregoing $7.0 million in proceeds.
• Existing stockholders will experience dilution if the warrants are exercised.
• The market price of the common stock could be adversely affected by the sale of shares issued upon exercise of the warrants.

Future Outlook

The company is required to hold additional meetings every 90 days to seek approval of the Nasdaq Proposal if it is not approved at the Special Meeting until the warrants are no longer outstanding or approval is received.

Management Comments

• The Company's Board has determined that each of the proposals that will be presented to the stockholders for their consideration at the Special Meeting are in the best interests of the Company and its stockholders, and unanimously recommends and urges you to vote FOR the proposals set forth in this Proxy Statement.
• Walter V. Klemp, Chairman of the Board and Chief Executive Officer, thanks stockholders for their continued support.

Industry Context

The need for shareholder approval for the warrant issuance is driven by Nasdaq Listing Rule 5635(d), which is a standard requirement to protect shareholders from excessive dilution in certain situations.

Comparison to Industry Standards

• Seeking shareholder approval for warrant exercises is a common practice among publicly traded companies, especially when the issuance could result in significant dilution.
• The engagement of a proxy solicitation firm like Okapi Partners LLC is also a standard practice to ensure sufficient shareholder turnout and voting on important proposals.
• The specific terms of the warrants, such as the exercise price and expiration date, would need to be compared to similar financing transactions in the biotech industry to assess their competitiveness.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution of their ownership if the warrants are exercised.
• The company's ability to raise capital and fund its operations could be affected by the outcome of the vote on the Nasdaq Proposal.

Next Steps

• Stockholders to vote on the Nasdaq Proposal and Adjournment Proposal at the Special Meeting on April 9, 2025.
• If the Nasdaq Proposal is not approved, the company will hold additional meetings every 90 days to seek approval.
• The company will file a Form 8-K with the SEC to disclose the voting results of the Special Meeting.

Key Dates